Palatin net loss narrows to $8.38 million in FY26; revenue turns to $13.19 million

• Palatin posted a net loss of $8.38 million, narrowing from $17.31 million a year earlier.
• Loss per share improved to $2.96 from $32.15 in the prior fiscal year.
• Revenue was $13.19 million versus no revenue a year earlier, including $9.4 million tied to Boehringer Ingelheim.
• Cash and cash equivalents rose to $7.49 million from $2.56 million at June 30, 2025; it flagged a need for additional funding.
• Phase 1 SAD/MAD for a once-weekly injectable MC4R peptide is targeted for 1H 2027, with initial data targeted in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palatin Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH57126) on September 28, 2026, and is solely responsible for the information contained therein.